Arndtz Katherine, Hirschfield Gideon M
Centre for Liver Research, NIHR Birmingham Liver Biomedical Research Unit, University of Birmingham, Birmingham, UK.
Dig Dis. 2016;34(4):327-33. doi: 10.1159/000444471. Epub 2016 May 11.
Autoimmune liver disease (AILD) encompasses 3 main distinct clinical diseases: autoimmune hepatitis, primary biliary cholangitis (formally known as cirrhosis, PBC) and primary sclerosing cholangitis (PSC). These conditions are an important, yet under-appreciated cause of patient morbidity and mortality with ongoing unmet needs for further research and clinical advances.
There is observational evidence for genetic predisposition, with all 3 conditions being more common in first degree relatives. AILD is associated with the presence of auto-antibodies and higher risks of other non-hepatic auto-immune conditions. Genetic risk association studies have identified HLA and non-HLA risk loci for the development of disease, with some HLA loci providing prognostic information. This re-enforces the concept that genetic predisposition to autoimmunity is important, likely in the context of environmental exposures. Such environmental triggers are unclear but relevant risks include smoking, drug and xenobiotic exposure as well as the complexities of the microbiome. There is evidence for a loss of immune tolerance to self-antigens playing a part in the development of these conditions. In particular the IL-2 and IL-12 regulatory pathways have been implicated in pre-disposing to an unopposed inflammatory response within the liver. Main immunological themes revolve around loss of immune tolerance leading to T-cell mediated injury, imbalance in the regulation of immune cells and defective immune response to foreign antigens. For PBC and PSC, there is then the added complexity of the consequences of cholestasis on hepato-biliary injury, immune regulation and liver fibrosis.
Whilst specific disease causes and triggers are still lacking, AILD arises on the background of collective genetic and environmental risk, leading to chronic and abnormal hepato-biliary immune responses. Effective and more rational therapy will ultimately be developed when the multiple pathways to liver injury are better understood.
自身免疫性肝病(AILD)包括3种主要的不同临床疾病:自身免疫性肝炎、原发性胆汁性胆管炎(以前称为原发性胆汁性肝硬化,PBC)和原发性硬化性胆管炎(PSC)。这些疾病是患者发病和死亡的重要原因,但尚未得到充分认识,对进一步研究和临床进展仍有未满足的需求。
有观察证据表明存在遗传易感性,这3种疾病在一级亲属中更为常见。AILD与自身抗体的存在以及其他非肝脏自身免疫性疾病的较高风险相关。遗传风险关联研究已经确定了疾病发生的HLA和非HLA风险位点,一些HLA位点提供预后信息。这强化了自身免疫性遗传易感性很重要的概念,可能是在环境暴露的背景下。这种环境触发因素尚不清楚,但相关风险包括吸烟、药物和外源性物质暴露以及微生物群的复杂性。有证据表明对自身抗原的免疫耐受性丧失在这些疾病的发生中起作用。特别是IL-2和IL-12调节途径与肝脏内无对抗性炎症反应的易感性有关。主要的免疫主题围绕免疫耐受性丧失导致T细胞介导的损伤、免疫细胞调节失衡以及对外源抗原的免疫反应缺陷。对于PBC和PSC,胆汁淤积对肝胆损伤、免疫调节和肝纤维化的影响又增加了复杂性。
虽然仍然缺乏具体的疾病病因和触发因素,但AILD是在遗传和环境综合风险的背景下发生的,导致慢性和异常的肝胆免疫反应。当更好地理解肝脏损伤的多种途径时,最终将开发出有效且更合理的治疗方法。